Observational study observes real-world clinical experience with oral desidustat in chronic kidney disease anemia, highlighting endogenous erythropoietin stimulation as an oral alternative.
Chronic kidney disease-associated anemia occurs due to low production of erythropoietin. The routine standard of care for anemia is erythropoietin and IV iron. Recently, a new oral drug was approved for management of CKD anemia- Desidustat, belonging to class HIF-PHIs that endogenously produces erythropoietin. This study was aimed to seeing real-world experience with Desidustat.
No takes yet. Share an insight, caveat, or question.
Rohit Rungta (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: